{"protocolSection":{"identificationModule":{"nctId":"NCT03289702","orgStudyIdInfo":{"id":"MT03-KR16MST907 (Phase3)"},"organization":{"fullName":"Medy-Tox","class":"INDUSTRY"},"briefTitle":"CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)","officialTitle":"A Randomized, Double-blind, Active Drug Controlled, Multi-Center, Phase I/III Clinical Trial to Evaluate the Efficacy and Safety of CORETOX® in Treatment of Post Stroke Upper Limb Spasticity"},"statusModule":{"statusVerifiedDate":"2021-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-11-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-06-30","type":"ACTUAL"},"completionDateStruct":{"date":"2018-11-09","type":"ACTUAL"},"studyFirstSubmitDate":"2017-09-19","studyFirstSubmitQcDate":"2017-09-19","studyFirstPostDateStruct":{"date":"2017-09-21","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-12-05","lastUpdatePostDateStruct":{"date":"2021-12-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Medy-Tox","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the efficacy and safety of CORETOX® in the treatment of post-stroke upper limb spasticity"},"conditionsModule":{"conditions":["Muscle Spasticity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":220,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"CORETOX®","type":"EXPERIMENTAL","interventionNames":["Drug: CORETOX®"]},{"label":"BOTOX®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: BOTOX®"]}],"interventions":[{"type":"DRUG","name":"CORETOX®","description":"Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.","armGroupLabels":["CORETOX®"]},{"type":"DRUG","name":"BOTOX®","description":"Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.","armGroupLabels":["BOTOX®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"MAS(Modified Ashworth Scale)of wrist flexor","description":"Change from baseline at week 4 for wrist flexor muscle tone as measured on the MAS(Modified Ashworth Scale)","timeFrame":"4 weeks"}],"secondaryOutcomes":[{"measure":"MAS(modified Ashworth Score)of elbow and finger flexor","description":"Change from baseline at week 4 for elbow flexor and finger flexor muscle tone as measured on MAS","timeFrame":"4 weeks after injection"},{"measure":"MAS(modified Ashworth Score)of wrist, elbow and finger flexor","description":"Change from baseline at week 8, 12 for wrist flexor, elbow flexor and finger flexor muscle tone as measured on MAS","timeFrame":"8, 12 weeks after injection"},{"measure":"Percentage of treatment responder at week 4, 8, 12 after injection","description":"A treatment response is defined as 1-point improvement on the MAS of injection site","timeFrame":"4, 8, 12 weeks after injection"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients ≥ 19 years\n* ≥ 6 months since the last stroke\n* ≥ 2 points in the focal spasticity of wrist flexor and ≥ 1 point at least one of elbow flexor and finger flexor as measured on MAS(0 to 4)\n* Informed consent has been obtained\n\nExclusion Criteria:\n\n* Neuromuscular disorders such as Lambert-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis\n* History(within 4 months of screening visit) or planned(during study period) treatment with phenol or alcohol injection or surgery in the target limb\n* History(within 4 months of screening visit) or planned(during study period) treatment with tendon lengthening in the target limb\n* Fixed joint/muscle contracture\n* Severe atrophy\n* Concurrent treatment with an intrathecal baclofen\n* Patients who have bleeding tendency or taking anti-coagulant\n* Dysphagia and Breathing Difficulties\n* History(within 4 months of screening visit) Planned(during study period) treatment with Botulinum Toxin\n* Known allergy or sensitivity to study medication or its components\n* Concurrent or planed Muscle relaxants and/or benzodiazepine medication If patient has taken these medication stable from one month before screening and no treatment changes are not planned during the study, participation is allowed.\n* Current Physical, occupational, Splinting therapy These therapy regimens will be permitted if they have been stable in the one month before screening; no treatment and no changes are planned during the study.\n* Patient who are participating in other clinical trials at the screening\n* Females who are pregnant, breastfeeding, or planning a pregnancy during the study period, or female of childbearing potential, not using a reliable means of contraception.\n* Patients who are not eligible for this study at the discretion of the investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Asan Medical Center","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}}]},"referencesModule":{"references":[{"pmid":"32497599","type":"DERIVED","citation":"Lee J, Chun MH, Ko YJ, Lee SU, Kim DY, Paik NJ, Kwon BS, Park YG. Efficacy and Safety of MT10107 (Coretox) in Poststroke Upper Limb Spasticity Treatment: A Randomized, Double-Blind, Active Drug-Controlled, Multicenter, Phase III Clinical Trial. Arch Phys Med Rehabil. 2020 Sep;101(9):1485-1496. doi: 10.1016/j.apmr.2020.03.025. Epub 2020 Jun 1."}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M250157","name":"abobotulinumtoxinA","relevance":"LOW"},{"id":"M20947","name":"Botulinum Toxins, Type A","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}